8-K
filed January 13, 2025, 6:59 PM ET
ticker CHRN
CIK 0001549084
earnings
confidence medium
sentiment positive
materiality 0.60
Ekso Bionics expects record Q4 2024 revenue of $5.0-$5.1M, preliminary
EKSO BIONICS HOLDINGS, INC.
2025-FY EPS
reported -$8.43
vs consensus -$0.29
▼ miss
(-2799.9%)
- Q4 2024 revenue estimated at $5.0-5.1M (company record vs $4.8M in Q4 2023).
- Cash $6.5M at Dec 31, 2024, down from $8.6M a year earlier.
- Net cash used in ops Q4 2024 estimated $1.5M, improving from $1.6M year ago.
- CEO highlights initial CMS reimbursement for Ekso Indego Personal device.
- Full Q4 and FY 2024 results expected in first week of March 2025.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001437749-25-000928
- form_type
- 8-K
- ticker
- CHRN
- cik
- 0001549084
- company_name
- EKSO BIONICS HOLDINGS, INC.
- filed_at
- 2025-01-13T23:59:59+00:00
- discovered_at
- 2026-05-14T18:03:03.963726+00:00
- generated_at
- 2026-05-28T03:16:16.784764+00:00
- sec_items
- ["2.02", "8.01", "9.01"]
- event_type
- earnings
- sentiment
- positive
- materiality_score
- 0.6
- calibrated_materiality_score
- 0.6
- confidence
- medium
- secwatch_canonical_url
- https://secwatch.observer/filing/0001437749-25-000928
- json_url
- https://secwatch.observer/filing/0001437749-25-000928.json
- markdown_url
- https://secwatch.observer/filing/0001437749-25-000928.md
- text_url
- https://secwatch.observer/filing/0001437749-25-000928.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1549084/000143774925000928/0001437749-25-000928-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1549084/000143774925000928/ekso20250108_8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
PD
PagerDuty Q1 revenue $121M up 1% YoY; new CEO DiLullo; $100M buyback
PagerDuty, Inc.
May 28, 2026, 4:07 PM ET
earnings
Items 2.02, 8.01, 9.01
same SEC item: 2.02, 8.01, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
NTAP
NetApp reports Q4/FY2026 results (details not in filing) and adds $1B buyback
NetApp, Inc.
May 28, 2026, 4:05 PM ET
earnings
Items 2.02, 8.01, 9.01
same SEC item: 2.02, 8.01, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
KSS
Kohl's Q1 net loss $14M; comparable sales down 1.1% YoY; affirms FY outlook
KOHLS Corp
May 28, 2026, 7:00 AM ET
earnings
Items 2.02, 7.01, 8.01, 9.01
same SEC item: 2.02, 8.01, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
SKY
Champion Homes Q4 sales up 4.6% to $621.3M; adjusted EPS $0.68; repurchase authorization increased $150M
Champion Homes, Inc.
May 26, 2026, 6:45 AM ET
earnings
Items 2.02, 8.01, 9.01
same SEC item: 2.02, 8.01, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
DEERE JOHN CAPITAL CORP
John Deere Capital Q2 net income up 22% to $151M, portfolio down 3%
DEERE JOHN CAPITAL CORP
May 21, 2026, 6:17 AM ET
earnings
Items 2.02, 7.01, 8.01, 9.01
same SEC item: 2.02, 8.01, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
DAVEY TREE EXPERT CO
Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M
DAVEY TREE EXPERT CO
June 1, 2026, 1:50 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
BKE
Buckle Q1 net income $46.9M ($0.93/share), sales up 6.1% to $288.7M
BUCKLE INC
May 29, 2026, 3:38 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
HIND
Vyome Q1 net loss $963K, cash $8.8M, inks JAK inhibitor licensing deal with Impetis
Vyome Holdings, Inc
May 29, 2026, 8:42 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.